[Molecular action mechanisms of the therapeutic agents for kidney diseases: Immunosuppressants].
Nishikido
Masaharu
M
Division of Nephro Urology, Course of Medical and Dental Sciences, Nagasaki University Graduate School of Biomedical Sciences.
Kanekake
Hiroshi
H
Harada
Takashi
T
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000077552:Basiliximab; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D005229:Fatty Acids, Monounsaturated; D000068876:Fingolimod Hydrochloride; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D007674:Kidney Diseases / Q000188:drug therapy*; D016030:Kidney Transplantation; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D011409:Propylene Glycols; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D012263:Ribonucleosides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D013110:Sphingosine / Q000031:analogs & derivatives
D000911:Antibodies, Monoclonal; D005229:Fatty Acids, Monounsaturated; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D011993:Recombinant Fusion Proteins; D012263:Ribonucleosides; C010052:mizoribine; D016572:Cyclosporine; D003520:Cyclophosphamide; D000077552:Basiliximab; D000068876:Fingolimod Hydrochloride; D009173:Mycophenolic Acid; D001379:Azathioprine; D013110:Sphingosine; C001996:thermozymocidin